PSC Partners Seeking a Cure

2024 Research Grants Program Impact Report



TABLE OF CONTENTS

PSC Partners mission is to drive research to identify treatments and a cure for primary sclerosing cholangitis (PSC), while providing education and support for those impacted by this rare disease. This report describes the impact of our Research Grants program since its launch in 2007.

Impact Report Section Name

Page Number

Letter from Leadership	1
Our Organization's Purpose	2
PSC Partners Research Programs	3
Strategic Research Planning: Program Priorities	4
History of the Research Grants Program	5
Recent Advances to Program Management	6
Grant Application Process	7
Grants Cycle and Grant Reporting Requirements	8
Scientific/Medical Advisory Committee (SMAC) Scores	9
Community Review Scores 1	0
Reviewers for SMAC and Community 1	11
Overall Program Impact and Reach 1	12
Current Grantees: 2024 Standard Seed Grants 1	13
Current Grantees: 2024 Young Investigator Grants 1	14
Impact Spotlights 1	15
Seed Grants Leading to Innovation	15
 Breakthroughs in PSC-CCA Research1 	6
Advancing Careers in PSC1	17
Looking Back: Full List of Historical Grants 1	8
Looking Ahead: Ways to Get Involved 1	8
References 1	19

Dear PSC Partners Community,

As our organization reflects on two decades of driving research and providing education and support for those impacted by primary sclerosing cholangitis (PSC), we are profoundly moved by the unwavering commitment of our community. Since the launch of the PSC Partners Research Grants program in 2007, PSC Partners has awarded 129 grants totaling \$5.15 million USD to drive pioneering research around the world.

Much of this funding has been made possible by the patient community —individuals, caregivers, and families who have transformed their personal experiences into a powerful force for change. Your contributions have propelled discoveries in basic, translational, and clinical science, driving better understanding of PSC and its treatment pathways.

In this report, we share the remarkable achievements of the Research Grants program, highlighting how patient-led funding decisions and strategic partnership with PSC Partners Canada and our SMAC have shaped the research landscape. These efforts have not only brought us closer to our ultimate goal — treatments and a cure for PSC — but have also significantly advanced the research of closely associated conditions like inflammatory bowel disease and cholangiocarcinoma.

To the donors, researchers, scientific and medical advisors, and the patient community individuals, caregivers, families, and friends who make this work possible: thank you for sharing our mission and vision.

With gratitude and hope,



Ricky Safer Founder and CEO PSC Partners Seeking a Cure



Stephen Rossi, PharmD Chief Scientific Officer PSC Partners Seeking a Cure



Audra Fleming Executive Director PSC Partners Seeking a Cure

About PSC Partners Seeking a Cure:



- Founded in 2005, PSC Partners Seeking a Cure is a 501(c)(3) nonprofit organization with a Canadian affiliate, PSC Partners Canada.
- Our mission is to drive research to identify treatments and a cure for primary sclerosing cholangitis (PSC), while providing education and support for those impacted by this rare disease.
- Our programs give support to patients, caregivers, families, and friends; educate patients and the medical community about PSC; and encourage ground-breaking research on PSC and closely associated diseases.

About PSC:

 PSC is a rare liver disease that damages the bile ducts inside and outside the liver (Chapman 2010, Karlsen 2024). Bile ducts become inflamed, and the inflammation leads to scarring and narrowing of the affected ducts. Eventually, blockages may occur.



- As the scarring blocks more and more ducts, bile becomes trapped in the liver. The scarring damages the liver and can result in fibrosis and cirrhosis of the liver and liver failure. Patients may eventually require a liver transplant.
- PSC is frequently associated with inflammatory bowel disease (IBD), particularly ulcerative colitis (UC) (Barberio 2021).
- Unfortunately, recurrent PSC occurs in 14%-25% of transplanted livers (Leung 2021). Additionally, patients with PSC are at increased risk of developing cholangiocarcinoma (CCA), a rare bile duct cancer (Karlsen 2024).
- Although the causes of PSC are unknown, research is underway to better understand the disease, develop effective treatments, and find a cure.

PSC Partners Research Grants program complements several other PSC Partners research programs and initiatives:



The **PSC Partners Patient Registry** gathers PSC patient-reported data to support research on patient experiences, recruit for and facilitate clinical trials, and provide a platform for patient surveys. Over 2,500 patients from 56 countries are currently participating.



The **International Collaborative Research Network** (**ICRN**) is a forum for global PSC experts and patient community members to collaborate on innovative research ideas and develop potential research proposals aligned with community priorities.



WIND-PSC is a patient-led global, prospective, multicenter observational study generating regulatoryquality data to support PSC drug development. It is actively enrolling up to 2,000 patients at up to 20 sites in North America and Europe.




The **PSC Symptom Assessment Project** is a patientpartnered development of PSC-specific patientreported outcome measures for potential use as validated clinical trial endpoints.



The **Acute Cholangitis Patient Experience Survey** is a collaboration between PSC Partners, PSC Support (UK), and the Forum for Collaborative Research/PSC Forum. It is a multi-national survey of patients experiencing an acute cholangitis attack and describing their symptoms, treatments, and access to care. Over 450 responses have been received to date.

The research grants program supports preclinical, clinical, and translational studies aligned with our organization's 4 priority areas for research programs:



Improve understanding of the mechanisms contributing to the development and progression of PSC


Further understanding of the gut-liver connection in PSC and PSC-IBD

Develop safe and effective treatments to slow progression and reduce symptom burden

Create early detection and treatment of PSC-related cholangiocarcinoma

These priority areas were identified through an extensive process which engaged patients, relatives, caregivers, researchers, clinicians, and other stakeholders. Over 500 individuals contributed their ideas over the course of 4 years. All programs include community support and education through patient engagement and knowledge translation.

PSC Partners Research Grants Program Funding Milestones:



- In 2007, PSC Partners officially announced the launch of the Research Grants program, aimed at funding seed grants for novel research projects to improve our understanding of disease progression and finding a cure for PSC.
- In 2009, PSC Partners awarded three grants of \$40,000 each to researchers from the Mayo Clinic, Rochester, the University of California, Davis, and the Academic Medical Center in the Netherlands.
- In 2016, PSC Partners Canada joined hands with us to fully fund their first research grant.
- In 2018, PSC Partners and PSC Partners Canada launched the Young Investigator Award category to fund up to \$80,000 to promising researchers who are at the early stages of their research career and are interested in clinical, translational, or basic research on PSC.
- In 2024, the award amounts increased to \$100,000 for Young Investigators and \$75,000 for Standard Seed Grants (total for 2 years).

RECENT ADVANCES TO PROGRAM MANAGEMENT

Sustaining Growth and Improving Experience

We are receiving record numbers of letters of intent (LOIs) and applications. In 2024, we received 38 LOIs and 25 applications. For the 2025 cycle, we received 43 LOIs and 38 applications.

We currently use Proposal Central, an online grants management platform. This is assisting with sustaining the program's growth, while improving both applicant and reviewer experiences. In its first year of use, we have already seen several key enhancements.

Five Key Enhancements:

- 1. Future Growth Opportunities of the Program - Positions the organization for expansion and new opportunities.
- 2. **Streamlined Submissions** Simplifies the application process for efficiency.
- 3. Accelerated Decision Making Speeds up the evaluation and approval stages.
- 4. **Impact Assessment** Measures the outcomes and effectiveness of funding.
- 5. **Enhanced Transparency** Ensures clarity and openness in the process.

s of the zation unities. mplifies ciency. - Speeds stages. es the






Applicants undergo a competitive and rigorous review process.

- Prospective applicants submit a Letter of Intent, which is screened by staff for eligibility and alignment with our priorities; if approved, investigators are invited to submit full applications.
- Applications are reviewed simultaneously by 2 distinct committees:
 - Our Scientific/Medical Advisory Committee (SMAC), comprised of expert researchers and clinicians, utilizes NIH scoring criteria to assess for scientific feasibility.
 - Our Community Review Committee, comprised of patients, caregivers, or other relevant stakeholders, utilizes our customized Community Rubric to assess for components such as mission and program alignment, overall reach, and impact.
- Initial scores are calculated and weighted 50/50 between the two committees. The agenda is set for committee discussions, where reviewers present their scores. Afterwards, all reviewers submit final scores. The topranking applications are selected for funding, based on the organization's funding capacity.
- PSC Partners Canada, a legal affiliate of PSC Partners, makes independent research grant decisions in compliance with Canadian charity law.
 - PSC Partners Canada participates in the Scientific Medical Advisory Committee scientific review process administered by US-based PSC Partners Seeking a Cure.
 - The Scientific/Medical Advisory Committee reviews all proposals and makes recommendations based on scientific merit.
 - The Canada Board of Directors determines if research grant(s) will be made by PSC Partners Canada.



The grants program has an annual cycle, starting with letters of intent (LOIs) and progressing to applications, reviews, funding decisions, and reporting:



GRANT REPORTING REQUIREMENTS

\langle	000	
		·

- PSC Partners staff conduct internal assessments on the impact, progress, and areas for growth of the grants program.
- Grant recipients provide a lay summary for the PSC Partners website and a first-year progress report for review by SMAC.
- Second year funding is contingent upon a successful review of the progress report.
- Grant recipients complete the 2nd year of the research project and submit a final report.

The Scientific/Medical Advisory Committee (SMAC) reviews the strengths and weaknesses of the applications based on the following criteria:



Significance:

Assesses whether the project addresses an important problem or critical barrier to progress in PSC research and evaluates the project's potential to advance scientific knowledge, technical capabilities, and/or clinical practice



Investigator(s):

Evaluates whether the research team is well suited for the project with specific focus on appropriate qualifications and training of young investigators and record of accomplishment for established investigators as well as the collaborative environment supporting the team



Innovation:

Considers how the project challenges current PSC research or clinical practice paradigms and proposes novel concepts or methodologies or offers significant refinement or improvement to current practices



Approach:

Examines the overall strategy, methodology, and analyses to ensure they are well-reasoned and appropriate to accomplish the specific aims of the project as well as how well potential challenges are addressed



Environment:

Considers the suitability of the research environment including institutional support, equipment, available resources, and collaborative opportunities



Additional Considerations and Overall Impact:

Evaluates whether the proposed protections meet acceptable ethical and safety criteria for human subjects and vertebrate animals, and provides an overall impact score ranging from exceptional (1) to poor (9) The community reviewers are comprised of patients, caregivers, or other relevant stakeholders. They utilize our customized PSC Partners Community Rubric to assess components such as mission and program alignment, overall reach, and impact.



Mission Alignment:

How likely is the proposal to drive research toward PSC treatments and a cure AND improve aspects of disease diagnosis, monitoring, symptoms, and management



Priority Alignment:

How does the proposal align with PSC Partners four research priority areas (refer to "Strategic Research Planning" on page 4)



Program Alignment:

Does the proposal directly complement or enhance existing PSC Partners research programs



Patient Partnerships:

Does the proposal include a patient partnership that is patient targeted, patient centered, or patient led.



Competitive Landscape:

How does the proposal bring unique value relative to existing research or similar projects



Community Impact:

How widely does the proposal impact the entire PSC patient population across all stages of the disease post-transplant, or post-transplant with recurrent PSC

Scientific/Medical Advisory Committee (SMAC) Chair:



Dr. Christopher Bowlus is the Lena Valente Professor of Medicine and the Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine. His extensive research is in autoimmune liver diseases, including the immunopathogenesis of PSC. He also chairs the Consortium for Autoimmune Liver Disease (CALiD) and is an active member of the International PSC Study Group (IPSCSG) and PSC Partners ICRN.

Additional SMAC Members:

- David Assis, MD
- Dennis Black, MD
- John Eaton, MD
- Richard Green, MD
- Bettina Hansen, PhD
- Gideon Hirschfield, FRCP, PhD
- Johannes R. Hov, MD

- Joshua Korzenik, MD
- Cynthia Levy, MD
- Cara Mack, MD
- Sonya MacParland, PhD
- Alexander Miethke, MD
- Yury Popov, MD, PhD
- Kidist Yimam, MD

Community Reviewers:

- Jesse Kirkpatrick, PhD
- Joanne Hatchett, RN, FNP, ACHPN
- Mahesh Krishna, MD

- Christine Lam, PhD
- James McMurtry, MD
- Stephen Rossi, PharmD

Ad Hoc Reviewers:

- Ad Hoc reviewers assist as needed, based on the number of applications received and the areas of expertise covered by reviewers
- Ad Hoc SMAC reviewers are approved by the SMAC chairs
- Ad Hoc Community reviewers are approved by the Board of Directors' Research Committee

PSC Partners | 2024 Annual Research Grants Program Impact Report

OVERALL PROGRAM IMPACT AND REACH

Since 2007, PSC Partners has awarded over \$5 million through several types of research grants:

- Standard Seed Grants funded between \$60,000 - \$75,000 for 2-year studies
- Young Investigator Awards funded between \$80,000 - \$100,000 for 2-year studies
- Other types of grants support collaborations with AASLD, EASL, CASL, and various patient partners





Our research grants have funded studies in **15 states** and **12 countries**:



Applicants are eligible for a Standard Seed Grant if they have an advanced terminal degree prior to the start of the grant period, have expertise in preclinical and/or clinical research, and are affiliated with an academic medical institution, research institution, or nonprofit/community-based organization. **In 2024, PSC Partners awarded two Standard Seed Grants and PSC Partners Canada awarded one:**

International Validation of Serum Protein Biomarkers for Predicting and Early Diagnosing Cholangiocarcinoma (CCA) in Individuals with Primary Sclerosing Cholangitis (\$60,000)

Jesus Banales, Ph.D. | Biodonostia Institute | Spain



- This study validates novel serum biomarkers (CRP, Fibrinogen, FRIL) for early detection of cholangiocarcinoma (CCA) in PSC patients. It aims to enhance non-invasive diagnosis using ELISA and predict cancer development before clinical symptoms appear.
- Dr. Banales is also the recipient of the PSC Partners' *Douglas Carlson Research Award for Exceptional Patient Partnerships,* acknowledging his incorporation of patient perspectives into the proposal's development and design.

Biomarkers for Risk Stratification in Primary Sclerosing Cholangitis (\$60,000)

Johannes R. Hov, M.D., Ph.D. | University of Oslo | Norway



 Leveraging data from an international study, this project evaluates blood markers, including the ELF test, to predict PSC progression, fibrosis, and outcomes over time. It also compares these markers with liver stiffness measurements to develop more precise diagnostic tools.

Molecular Mechanisms Regulating Neutrophil-Induced Oxidative Stress in Primary Sclerosing Cholangitis (\$60,000)

Nidhi Jalan-Sakrikar, Ph.D. | Mayo Clinic | USA 🔰



 This study, funded by PSC Partners Canada, examines how neutrophils, key immune cells, contribute to chronic inflammation and tissue damage in PSC. Using pharmacological inhibitors and animal models, it aims to develop therapies that reduce neutrophil infiltration and liver fibrosis.

Applicants are eligible for a Young Investigator Award if they meet the following criteria:

- Are in training or within five years post-training or degree.
- Have completed an advanced terminal degree prior to the start of the grant period.
- Are affiliated with an academic medical institution, research institution, or nonprofit/community-based organization.
- Have a mentor or willingness to work with one if needed for the project.

PSC Partners awarded these Young Investigator Awards in 2024:



The Transcription Factor RUNX1 is Pivotal in TGFβ-activated Cholangiocyte Signaling with the Immune System in PSC (\$80,000)

Sayed Obaidullah Aseem, M.D., Ph.D. | Virginia Commonwealth University | USA

• This Young Investigator researches how the transcription factor RUNX1 influences bile duct cells and their communication with immune cells to drive fibrosis. The project uses genetic models to delete RUNX1 and examines its potential as a target for reducing inflammation and scarring in PSC.



Portal Fibroblasts as Targets to Limit Liver Fibrosis in PSC (\$80,000)

Sara Lemoinne, M.D., Ph.D. | Sorbonne Université | France

• This Young Investigator focuses on the role of portal fibroblasts in liver fibrosis in PSC. Using genetically modified mice, it identifies molecular triggers driving scarring and explores how signals from the gut influence these processes, with the goal of developing anti-fibrotic therapies.



Steven P. O'Hara, PhD Associate Professor of Medicine Mayo Clinic, Rochester, Minnesota

Recipient of PSC Partners Canada's Standard Seed Grant in 2016 and of PSC Partners Standard Seed Grant in 2021

Dr. Steven O'Hara has previously received multiple PSC Partners Seed Grants (2016 & 2021). These grants enabled him to explore more complex questions and create new opportunities in PSC research specifically in studying the role of senescent cholangiocytes (epithelial cells that line bile ducts which can no longer undergo cell division and drive fibrosis and inflammation) in PSC and the role of the bromodomain and extra-terminal domain (BET) proteins in maintaining the cholangiocyte senescence-associated inflammatory secretome.

Key Achievements and Impact:

- **Recent Recognition**: Dr. O'Hara is one of the eight winners of the prestigious 2024 American Liver Foundation (ALF) Pilot Research Awards for his highly innovative research on BET protein function in PSC.
- Additional Funding: Dr. O' Hara has secured \$50,000 in funding for one year from ALF for this "high-risk, high reward" project that has the potential to generate breakthrough findings and significantly advance PSC research.
- Prestigious Publication: The study titled "The Epigenetic Reader, Bromodomain Containing 2, Mediates Cholangiocyte Senescence via Interaction With ETS Proto-Oncogene 1" (<u>Kang et al</u>., 2023) was published in the prestigious journal of <u>Gastroenterology</u>

The seed grant allowed for the accumulation of data that provide preliminary data for and form the basis of further funding and aided in getting our data published in Gastroenterology.



Yury Popov, MD, PhD Associate Professor of Medicine Beth Israel Deaconess Medical Center - Harvard

Recipient of PSC Partners Canada's Standard Seed Grant in 2017

In 2017, Dr. Yury V. Popov received a seed grant from PSC Partners Canada to investigate cholangiocarcinoma (CCA), a deadly liver and bile duct cancer linked to PSC. With limited effective therapies and high mortality rates in PSC-associated CCA patients, his study, *"Integrin \alpha\nu\beta 6 as a Therapeutic Target for Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma"* aimed to address the absence of reliable animal models and potential therapeutic approaches for this challenging condition.

Key Achievements and Impact:

- **Development of a Novel Animal Model:** Dr. Popov's team developed the SB CCA.Mdr2-/- mouse model, the first robust tool to replicate PSC-like susceptibility to CCA.
- **Identification of Key Drivers:** The study identified TGF β signaling and immune dysregulation as crucial drivers of PSC-CCA. It also introduced integrin $\alpha\nu\beta6$ as a potential therapeutic target.
- **AI-Powered Tumor Analysis:** The team used automated AI tools to conduct precise tumor burden and desmoplastic feature analysis.
- Leveraging Additional Funding: The success of this seed-funded study helped Dr. Popov secure additional NIH NIDDK funding (R01DK139288).
- **Prestigious Publication:** The study titled, "Transposon-based Oncogene Integration in Abcb4(Mdr2)-/- Mice Recapitulates High Susceptibility to Cholangiocarcinoma in Primary Sclerosing Cholangitis" (Huang et al., 2024), was published in the esteemed *Journal of Hepatology*. Link to full article

"This work would not be possible without recognition of importance of this work and two-year pilot grant from PSC Partners Seeking a Cure Canada."

Dr. Michael Li | University of California, San Francisco | USA Recipient of 2022 Young Investigator Award



"The PSC Partners Young Investigator Award has been transformative for my career; this grant has helped me build cross-disciplinary collaborations and has opened doors for me to directly interact with preeminent PSC investigators from around the world."

- Dr. Li

Key Achievements and Impact:

- The PSC Partners Young Investigator Award has catalyzed Dr. Li's development as an investigator studying immune-mediated liver disease.
- This PSC Partners grant in part supported Dr. Li's promotion from Instructor of Medicine to Assistant Professor of Medicine at UCSF.
- This research has garnered Dr. Li several invitations to speak at both institutional and national meetings and participate in the 2023 and 2024 International Collaborative Research Network (ICRN) meetings led by PSC Partners.
- Dr. Li's research funded by PSC Partners has led to an active multi-center collaboration with Stanford University.
- The data generated from his research helped him secure commitment to collaboration with The Consortium for Autoimmune Liver Diseases (CALiD) to access 200 additional patient samples intended for use in a future R01 submission.



LOOKING BACK: FULL LIST OF HISTORICAL GRANTS

NCHENG WEI

ESPEN MELUM

FANYIN MENG

Cholangitis

2020

PSC

in Bile Acid Synthesis and

Defining the Interactome of

Bile Duct Inflammation in

The Beneficial Effects of

in Primary Sclerosing

Endothelial Progenitor Cells

STEPHANIE ROESSLER &

Intraductal Papillary Neoplasia

of the Bile Duct in Patients with

Primary Sclerosing Cholangitis

Micro-RNA Based Therapy for

Primary Sclerosing Cholangitis

Transcription Factor 4 in Primary

PASQUALE PICCOLO

XIAOYING LIU

The Role of Activating

Sclerosing Cholangitis

JOY XIAOSONG JIANG

YOON-YOUNG JANG

Therapy

YU DU

Treating PSC with Idebenone

Human Disease Model of PSC

for Discovery of Effective PSC

2020 AASLD/PSCP Pilot Award

Cholangitis by Bioengineered in

Studying Primary Sclerosing

vitro Vascular Biliary Model

BENJAMIN GOEPPERT

Integrative Analysis of

Primary Sclerosing Cholangitis

2023

JESUS BANALES International Validation of Serum Protein Biomarkers for Predicting and Early Diagnosing Cholangiocarcinoma (CCA) in Individuals with Primary Sclerosing Cholangitis (PSC)

JOHANNES R. HOV Biomarkers for Risk Stratification in Primary Sclerosing Cholangitis (PSC)

SARA LEMOINNE Portal Fibroblasts as Targets to Limit Liver Fibrosis in PSC

SAYED OBAIDULLAH ASEEM The Transcription Factor RUNX1 is Pivotal in TGFB-activated Cholangiocyte Signaling with the Immune System in PSC

NIDHI JALAN-SAKRIKAR 🗯 Molecular Mechanisms Regulating Neutrophil-Induced Oxidative Stress in Primary Sclerosing Cholangitis (PSC)

GRANT

RESEARCH

HEATHER FRANCIS & **GIANFRANCO ALPINI**

Targeting PSC Pathogenesis Using a Bifunctional Peptide. GP119, in the Mdr2-/- Mouse Model of PSC and Novel Multicellular Human-Derived 3D PSC Organoids

ALYSSA KRIEGERMEIER Hepatic Unfolded Protein Response (UPR) in Murine Models of PSC

MICHAEL LI & JOSEPH DeRISI Novel Proteome-Wide 7Autoantibody Discovery in Primary Sclerosing Cholangitis

RINSE K. WEERSMA Unraveling the Immune Triggers of Primary Sclerosing Cholangitis With and Without Concomitant Inflammatory

Bowel Disease

МАМАТНА ВНАТ Closing the Gap: Machine Learning Evaluation of Liver Transplant Wait-List Prioritization for Patients with Primary Sclerosing Cholangitis

JOSHUA ELIAS 💡 Unbiased Tissue Metabolomic Profiling of PSC-IBD

RICHARD M. GREEN 🗯 Unfolded Protein Response (UPR)-based therapies in a mouse model of PSC

JOHANNES R. HOV Targeting GPR35 to Treat Cholangiocarcinoma

TOM HEMMING KARLSEN PSC Studies using a Bile-Duct-on-a-Chip

THEMISTOKLIS **KOURKOUMPETIS &** JAMES TROTTER Update on Primary Sclerosing Cholangitis Liver Waitlist and Post-Transplant Outcomes: Presentation of UNOS and Longitudinal Individual Center Data

STEVEN P. O'HARA Do BET Proteins Influence the Cholangiocyte Response to Injury and Are They Therapeutic Targets for PSC?

EVAGGELIA LIASKOU 🕊 Exploring the Metabolic Profile of T Cells in Patients with PSC

ALAN C. MULLEN MD, PHD & DANIEL S. PRATT The Role of E3 Ligase HRD1

Creation of Liver Organoids from Pluripo-tent Stem Cells Derived from Donors with Primary Sclerosing Cholangitis (PSC)

JOEL PEKOW 🏓

Mucosal Markers to Predict the Onset of Colonic Neoplasia in Inflammatory Bowel Disease Patients with Primary Sclerosing Cholangitis (PSC)

2019 JESÚS M. BAÑALES

Metabolomic-based prediction of prognosis in patients with primary sclerosing cholangitis, an early diagnosis of cholangiocarcinoma new non-invasive strategy

CYRIEL Y. PONSIOEN Single-cell RNA sequencing of lymphocyte subsets and cholangiocytes in non-endstage PSC patients

LEWIS R. ROBERTS Genome Wide Association Study (GWAS) in biliary tract cancer

(BTC) ORITH WAISBOURDZINMAN Pathways of injury and repair of the extrahepatic biliary tree in

GIANFRANCO ALPINI DAVID ASSIS ANNIKA BERGQUIST MICHAEL CHOI ALIYA GULAMHUSEIN CHANTAL HOUSSET

WEI-YU LU VERONICA MILLER MARIO STRAZZABOSCO

RICHARD M GREEN MARK DENEAU DAVID J. KATZMANN DAVID ELLINGHAUS KONSTANTINOS N. LAZARIDIS & TOM HEMMING KARLSEN MASSIMO PINZANI YURY V. POPOV

JESSICA ALL EGRETTI

RODRIGO LIBERAL

RINSE K. WEERSMA

RAMILLE SHAH

WEICI ZHANG

RUDI ALBERTS

ULRICH BEUERS

LISA B. BOYETTE

GIANNA HAMMER

GUOXIANG YANG

ROMINA FIOROTTO.

STEFANO FIORUCCI.

HEATHER FRANCIS

SHARON DEMORROW

NICHOLAS F. LARUSSO

EVAGGELIA LIASKOU,

STEVEN P. O'HARA, JAMES

GIDEON M. HIRSCHFIELD &

ALEXANDER G. MIETHKE

BARBARA RENGA

H. TABIBIAN

EVA ELLINGHAUS. ANDRE

MARIO STRAZZABOSCO,

TOM HEMMING KARLSEN

ESPEN MELUM

2013

FRANKE

2015

MARIA EUGENIA GUICCIARDI JOHANNES R. HOV TOM HEMMING KARLSEN STEVEN P. O'HARA MARIO STRAZZABOSCO

AASLD AWARDS

MELINDA WANG, 2023 NIDHI JALAN-SAKRIKAR, 2021 VIK MEADOWS, 2020 OMAR Y. MOUSA, 2019 ANGELA C. CHEUNG. 2018 MARK DENEAU, 2017 EMINA HALILBASIC, 2016 BRIAN D. JURAN, 2015 **MOHAMMED NABIL QURAISHI, 2014** JAMES H. TABIBIAN. 2013 LINA LINDSTROM. 2012 BRIAN D. JURAN, 2011 J. EATON, 2010 V.S. TEABERRY, 2009 P.G. BLANCO, 2008 ISTVAN TORNAI, 2008 TOM HEMMING KARLSEN, 2007

CASL

AUDREY-ANNE LAOVOI, 2024 DIANA NAKIB. 2023 M. ISMAIL, 2022 **BELLAL JUBRAN, 2021** JULIAN HERCON, 2020

LOOKING AHEAD: WAYS TO GET INVOLVED

There are many ways to participate in the Research Grants program:



Submit an LOI during our 💺 next review cycle Fall 2025



Mentor an applicant and spread the word about funding opportunities



Become an Ad Hoc reviewer (community or scientific)



Donate to the program to support future research proposals

Thank you to all the applicants, grantees, mentors, reviewers, and other supporters who've helped grow the grants program!

Contact grants@pscpartners.org to get involved or learn more.

18

SRIDHAR MANI CARLO SELMI MARIO STRAZZABOSCO

Funded by PSC Partners Seeking A Cure Canada



TIM O. LANKISCH

GEOFF BALDWIN

SHI-YING CAI &

JUDY CHO

JAMES L. BOYER

RINSE K. WEERSMA

2011

2010

PATRICK S.C. LEUNG

MARK S. SILVERBERG

NICHOLAS F. LARUSSO

Barberio, B., Massimi, D., Cazzagon, N., et. al (2021). Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: A systematic review and metaanalysis. Gastroenterology, 161(6), 1865-1877. https://doi.org/10.1053/j.gastro.2021.08.032

Chapman, R., Fevery, J., Kalloo, A., et. al (2010). Diagnosis and management of primary sclerosing cholangitis. Hepatology (Baltimore, Md.), 51(2), 660–678. https://doi.org/10.1002/hep.23294

Huang, P., Wei, G., Kirkpatrick, J. D., Lin, Y., Tan, L., Matta, H., Nasser, I., Huang, M., Chen, L., Petitjean, M., Skelton-Badlani, D., Gao, W., Vaid, K., Zhao, S., Lugovskoy, A., Alenzi, M., Chen, X., Gores, G. J., & Popov, Y. V. (2024). Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2024.07.016

Kang J. H., Splinter, P. L., Trussoni, C. E. Pirius, N. E., Gores, G. J., LaRusso, N. F. & O'Hara, S. P. (2023). The Epigenetic Reader, Bromodomain Containing 2, Mediates Cholangiocyte Senescence via Interaction with ETS Proto-Oncogene 1. Gastroenterology, 165(1), 228-243.e2.

Karlsen, T. H., Kaasen Jørgensen, K., & Bergquist, A. (2024). Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going? Hepatology. https://doi.org/10.1097/hep.000000000001172

Leung, K., Deeb, M., Fischer, S., et. al (2021). Recurrent primary sclerosing cholangitis: current understanding, management, and future directions. Seminars in Liver Disease, 41(3), 409-420. https://doi.org/10.1055/s-0041-1730950



- Visit <u>www.pscpartners.org</u> to learn more about PSC Partners
- Visit <u>www.pscpartners.ca</u> to learn more about PSC Partners Canada

PSC Partners | 2024 Annual Research Grants Program Impact Report